medigraphic.com

2014, Number 1

Rev Hematol Mex 2014; 15 (1)

Castleman’s Disease

Nolasco-De la Rosa AL, Mosiñoz-Montes R, Román-Guzmán E, Hernández-Quintero JM, Reyes-Miranda AL, Quero-Sandova Fl

Language: Español
References: 8
Page: 21-25
PDF size: 305.37 Kb.


ABSTRACT

Castleman’s disease, described in 1954, is a linfoproliferative, benign, low-frequent disorder. There are two histologic kinds of this disorder: hialinovascular type (90%) and plasmatic cell type, the latter can be associated to fever, weight loss, dermic eruption, anemia and hipergammaglobulinemia; the most common affected places are thorax, stomach and neck; it can also develop (but less frequently) on pelvis and pancreas. Its etiopathology is confusing and includes the interleukine 6 expression and the probable association with the 8-type human herpes virus. The only curative treatment is the surgical excision. This paper reports the case of a 55-year-old male patient with hyalinovascular Castleman’s disease and thoracic localization.

References

  1. Aguiar RM, Acevedo AP, Staffieri R. Enfermedad de Castleman: Presentación de un caso clínico. Fundación Dr. JR Villavicencio 2005:57-59.

  2. Camacho R, Millán F, Scher P, Castrillón C, Panzuto O. Enfermedad de Castleman. Presentación de un caso y revisión bibliográfica. Rev Cir Infantil 2008; 14:51-54.

  3. O’ReillyPE Jr, Joshi VV, Holbrook CT, Weisenburger DD, et al. Multicentric Castleman’s disease in a child with prominent thymic involvement: A case report and brief review of the literature. Mod Pathol 1993;6:776-780.

  4. Garcipérez VF, Vega J, Fernández H, Mogollón M, Porro R. Enfermedad de Castleman que infiltra grandes vasos y aurícula derecha. Rev Esp Cardiol 2012;65:669-675.

  5. Castleman B, Towne VW. Case report of Massachusetts General Hospital case 40011. N Engl J Med 1954;250:26-35.

  6. 6 Bandera B, Ainsworth C, Shikle J, Rupard E, Roach M. Treatment of unicentric Castleman disease with neoadjuvant rituximab. Chest 2010;138:1239-1241.

  7. Regal MA, Aljehani YM, Bousbait H. Primary mediastinal Castleman’s disease. Rare Tumors 2010;2:11-12.

  8. Sobrevilla CP, Aviles SA, Cortés PD, Rivas VS. Características clínicopatológicas de la enfermedad de Castleman. Experiencia en el Instituto Nacional de Cancerología. Cir Ciruj 2009;77:187-192.

2020     |     www.medigraphic.com